Noble Capital analyst Robert LeBoyer initiated coverage of NeuroSense (NRSN) with an Outperform rating and $9 price target Lead product PrimeC has completed two Phase 2 trials for Amyotrophic Lateral Sclerosis and has a Phase 3 trial planned for early 2026, notes the analyst, who adds that initial results from a Phase 2 study in Alzheimer’s disease showed “promising data.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRSN:
- NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeC
- NeuroSense announces ‘positive’ results from Phase-2b PARADIGM study
- NeuroSense Therapeutics Approves Resolutions at Annual Meeting
- NeuroSense Reports Positive Initial Results for Alzheimer’s Drug Candidate
- NeuroSense Therapeutics Reports Promising Phase 2b Study Results for ALS Treatment